



Nano-Drug Delivery for Cancer Treatment

Guest Editor:

Dr. Jason S. Buhrman

Department of Medicine,
University of Rochester Medical
Center, Rochester, NY 14642, USA

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editor

The field of drug delivery concerned with directing and augmenting the effects of agents used in anti-neoplastic therapy has produced several technologies which are now in clinical use. As the field continues to produce useful products, research in useful materials, as well as their creation, properties, and application, will drive the next generation of therapeutics.

Stages of this development pipeline begin with creation of novel materials that can be scaled to nano-delivery systems, or with the re-application of established systems engineered with novel mechanisms to improve their application to a wider range of payloads or targets. The next stage of the pipeline explores the therapeutic properties of these delivery systems when they specifically accumulate in a targeted cancer environment, or the side effects when they non-specifically accumulate in off-target sites. The final stage of the pipeline explores the overall therapeutic efficacy of these delivery systems—either front-line, or in disease that has no established treatment.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)